Background: Chromosomally encoded AmpC β-lactamases may be acquired by transmissible plasmids which consequently can disseminate into bacteria lacking or poorly expressing a chromosomal bla AmpC gene. Nowadays, these plasmid-mediated AmpC β-lactamases are found in different bacterial species, namely Enterobacteriaceae, which typically do not express these types of β-lactamase such as Klebsiella spp. or Escherichia coli. This study was performed to characterize two E. coli isolates collected in two different Portuguese hospitals, both carrying a novel CMY-2-type β-lactamase-encoding gene. Findings: Both isolates, INSRA1169 and INSRA3413, and their respective transformants, were non-susceptible to amoxicillin, amoxicillin plus clavulanic acid, cephalothin, cefoxitin, ceftazidime and cefotaxime, but susceptible to cefepime and imipenem, and presented evidence of synergy between cloxacilin and cefoxitin and/or ceftazidime. The genetic characterization of both isolates revealed the presence of bla CMY-46 and bla CMY-50 genes, respectively, and the following three resistance-encoding regions: a Citrobacter freundii chromosome-type structure encompassing a blc-sugE-bla CMY-2-type -ampR platform; a sul1-type class 1 integron with two antibiotic resistance gene cassettes (dfrA1 and aadA1); and a truncated mercury resistance operon.
Background
AmpC β-lactamases, along with Class A β-lactamases, are a major group of clinically important enzymes [1, 2] . They belong to class C according to the Ambler classification and to group 1 following the functional classification of Bush-Jacoby [3, 4] , whose prevalence is increasing worldwide [1] ; these β-lactamases are associated with infections caused by pathogenic Gram-negative bacteria, particularly Escherichia coli and Klebsiella pneumoniae. The identification of isolates containing plasmid-mediated AmpC-β-lactamase (PMAβ) is epidemiologically and clinically relevant due to the limitations of treatment options [5] .
AmpC enzymes hydrolyse amino-and ureidopenicillins, and cephamycins (cefoxitin and cefotetan) and, at a low level, oxyiminocephalosporins (ceftazidime, cefotaxime, and ceftriaxone) and aztreonam: they are not inhibited by β-lactamase inhibitors such as clavulanic acid [1] . AmpCproducing isolates are susceptible to carbapenems and to zwitterionic cephalosporins (cefepime and cefpirome).
In this study, we performed the phenotypic and molecular characterization of two new CMY-2-types (designated CMY-46 and CMY-50), both encoded by probably chromosomal inducible ampC genes, produced by two clinical E. coli isolates. The genetic environment of bla CMY-46 and bla CMY-50 was also investigated.
Methods

Bacterial isolate collection
Two clinical E. coli strains (INSRA1169 and INSRA3413) were isolated, in 1999, from urine samples of two patients of 77 years and 7 months old, in two different hospitals in Portugal. E. coli DH5α (pBK-CMY-2) strain was used as control for antimicrobial susceptibility tests.
Antimicrobial susceptibility tests
Minimal inhibitory concentrations were determined by a microdilution method according to guidelines of the French Society of Microbiology (SFM 2013, http://www. sfm-microbiologie.org/) against seven β-lactams, alone or in combination with clavulanic acid, and against ciprofloxacin, gentamicin and trimethoprim. Isolates non-susceptible to one third-generation cephalosporin, cefoxitin and/or exhibiting synergy with boronic acid and/or cloxacillin, were considered as presumptive AmpC producers. Imipinem and clavulanic acid were used in order to identify induction effect of AmpC [1, 6] . Disks of inducing agents (imipenem 10 μg and amoxicillin plus clavulanic acid 25 + 10 μg) and disks of cephalosporins (cefotaxime 30 μg and ceftazidime 30 μg) were placed on Mueller-Hinton agar plates, 20 mm apart. Positive induction was demonstrated by the antagonism effect surrounding the cephalosporin disks adjacent to the inducers.
Isoelectric point determination
β-Lactamases were characterized by isoelectric focusing of ultrasonicated bacterial extracts with the control strains expressing pI 5.2, 5.6, 7.6, 9.0, 9.2, as previously described [7] .
Molecular characterization of ampC and ESBL-encoding genes
The presence of acquired ampC (bla CMY , bla MOX , bla FOX , bla LAT , bla ACT , bla MIR , bla DHA , bla MOR , bla ACC ) and bla ESBL genes (bla TEM , bla SHV , bla OXA-1-type , bla CTX-M ) was investigated by multiplex PCR assays with primers and conditions as described elsewhere [7] [8] [9] [10] , and those from Table 1 . Controls were included in all assays.
Gene transfer experiments
Transferability of the bla CMY genes was attempted by both broth mating-out assays and electroporation. Conjugation experiments were performed at 37°C, using recipient strains E. coli C600 Rif R , Str R and E. coli J53 NaN 3 R , according to the antibiotic susceptibilities of the clinical isolates used as donor. Transconjugants were selected on MacConkey agar plates containing 250 μg/ml of rifampicin, 160 μg/ml of streptomycin or 160 μg/ml of sodium azide plus 10 μg/ml of cefoxitin. Plasmid DNA was extracted from clinical strains, using the Wizard Plus Midipreps DNA Purification kit (Promega), and used to transform electrocompetent E. coli DH5α ΔampC by electroporation, as previously described [7] . Transformants were selected on Luria broth medium containing 10 μg/ ml of cefoxitin.
Cloning experiments
The bla CMY-2 , bla CMY-46 and bla CMY-50 genes were amplified with iProof TM High-Fidelity DNA Polymerase (Bio-Rad, Hercules, CA), using primers from Table 1 . Amplicons (1169 bp) were ligated in the SmaI site of the phagemid pBK-CMV (Stratagene) downstream of its inducible lacZ promoter and transformed into electrocompetent E. coli DH5α ΔampC cells. A gene Pulser II apparatus (Bio-Rad, Hercules, CA) was used for standard electroporation techniques, as previously described [7] . Recombinant bacteria were selected on LB agar plates containing 10 μg/ml of cefoxitin.
Genetic background characterization
The presence of class 1 integrons was determined in both isolates through PCR amplification of the integrase-specific intI1 gene with the same specific primers and conditions as reported previously [11] (Table 1) . PCR-mapping and sequencing of the genetic environment of bla CMY-46 and bla CMY-50 was performed using primers targeting genes known for promoting antibiotic resistance and integrons (Table 1) . Sequence alignments and generation of resistance cassette contigs were performed using Bionumerics (Applied Maths). Gene identity was confirmed at the NCBI website (http://www.ncbi.nlm.nih.gov/).
Findings
The two clinical E. coli isolates INSRA1169 and INSRA3413 were resistant to amoxicillin, amoxicillin plus clavulanic acid, cephalothin, cefoxitin, ceftazidime, cefotaxime, gentamicin and trimethoprim, but susceptible to cefepime and imipenem (Table 2 ). INSRA1169 was also nonsusceptible to ciprofloxacin. Synergy between cloxacillin and cefoxitin plus cefotaxime and boronic acid, along with the absence of synergy between extended-spectrum cephalosporins and clavulanic acid, suggest that the resistance to extended-spectrum cephalosporins was mediated by the overproduction of AmpC β-lactamases. The resistance phenotype was not transferable, neither in conjugation assays with E. coli C600 as a recipient, or in transformation assays by electroporation of plasmid-DNA preparations into E. coli DH5α. This might suggest a chromosomal location of AmpC-encoding genes.
Transformants, obtained after cloning of DNA amplicons of INSRA1169 and INSRA3413 in pBK-CMV plasmid vector (Figure 1a) , showed a resistance phenotype similar to that of clinical isolates. However, they were susceptible to ciprofloxacin, gentamicin and trimethoprim, like the control strain E. coli DH5α (pBK-CMY-2) ( Table 2 ). Both the clinical strains and the transformants produced β-lactamases exhibiting an alkaline isoelectric point (pI 9.2) compatible with AmpC-type β-lactamases. Indeed, PCR revealed the absence of bla ESBL genes plus the presence of chromosomal E. coli ampC-type gene; the sequence of cloned DNA fragments identified two new CMY-2-like genes, which were not related to chromosome-mediated E. coli AmpC gene. The chromosomal location of such genes has only been observed in Salmonella spp. and Proteus mirabilis isolates [12] [13] [14] .
The deduced amino acid sequences confirmed that the new genes encoding the β-lactamases CMY-46 (in INSRA1169) and CMY-50 (in INSRA3413), which were new variants of CMY-2, differed by 9 and 13 amino acid substitutions, respectively (Table 3) . Two of these mutations (Q193K plus P208A for CMY-46 and N194S plus D198N for CMY-50) are in the Ω loop (between amino acids 178 and 226), which interacts by hydrogen bonding with helix H-2 close to the active Ser64. Substitutions in this region have been linked to the extension of the hydrolysis spectrum [15] . However, CMY-46 and CMY-50 β-lactamases did not confer resistance to cefepime and conferred low level of resistance to ceftazidime and cefotaxime, which suggests that, in contrast to extended-spectrum AmpCs, they have moderate or no extended-spectrum activity (Table 2 ) [15] [16] [17] [18] .
The study of sequences surrounding bla CMY-46 and bla CMY-50 revealed the presence of the blc gene (encoding an outer membrane lipoprotein) and the sugE gene (encoding a small MDR protein responsible for resistance to quaternary ammonium compounds) downstream of their open reading frames (Figure 1a) . Upstream, an ampR gene encoding the usual transcriptional regulator of ampC genes was observed in an opposite direction of transcription (Figure 1a) . The presence of an intact ampC-ampR segment in both new bla CMY genetic regions implied that the production of CMY-46 and CMY-50 is inducible, which was corroborated by the used phenotypic induction method. This ampCampR region was identical to the sequence flanking the bla AmpC gene in the C. freundii chromosome [6] , except for AmpR (that had 4 amino acid substitutions), but none were located in the helix-turn-helix region or in other E. coli EcDH5α (pBK-CMY-2) was control strain; E. coli DH5α (pBK-CMY-46) and E. coli DH5α (pBK-CMY-50) were transformants of E. coli INSRA1169 (harboring CMY-46 and TEM-1 enzymes) and E. coli INSRA3413 (harboring CMY-50 enzyme), respectively; E. coli EcDH5α was the recipient strain. positions related to AmpR function [20, 21] . The promoter regions of our bla CMY-2-type and ampR genes harbored no sequence element associated with increased strength of the promoter [20, 21] . In addition, the frdD, frdC, and frdB genes that are usually adjacent to ampC-ampR in the C. freundii chromosome were not identified in the sequences flanking bla CMY-46 or bla CMY-50 . Class 1 integrons, also detected in INSRA1169 and INSRA3413 (Figure 1b) , comprised the integrase-encoding gene intI1, two gene cassettes, aacA1 and dfrA1, and qacEΔ1 plus sul1, which were probably responsible for the observed resistances to trimethoprim and aminoglycosides.
We also found a truncated mercury resistance operon (Figure 1c) , which was previously reported as belonging to a "kan region" that included a kanamycin resistance gene [22] . This finding is of concern since mercury resistance may help to promote antibiotic resistance through indirect selection [23] .
In summary, this study describes two new bla CMY-2-type genes located within a C. freundii-derived fragment. Considering that CMY-type β-lactamases, detected in E. coli, are derived from the C. freundii chromosomal AmpC [1] and that chromosome-derived genes are usually mobilized by MGE [24, 25] resistance regions with diverse resistance determinants and MGE in this study, suggests the dynamics of bacteria in the transference of antibiotic resistance. In addition, they might also trigger the future emergence and spread of these resistant determinants both at a chromosomal or/and plasmid level.
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